AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00523042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled human insulin
Description: Treat-to-target dose titration scheme, inhalation.
Study NCT05032079 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryoablation
Description: single probe ultrasound guided cryoablation
Study NCT04223830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exalt Model D Single-Use Duodenoscope
Description: Subjects will have a clinically indicated per standard of care endoscopic retrograde cholangiopancreatography (ERCP) or other duodenoscope-based procedure performed with the Exalt single use duodenoscope study device.
Study NCT03291704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal therapy device
Description: Thermal therapy of blocked Meibomian glands
Study NCT00931554 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative drain removal
Description: removal of postoperative drainages at different time points (postoperative day 3 versus postoperative day 5)
Study NCT01822977 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: omeprazole
Study NCT02652143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AneVivo (Medical device for in vivo culture of embryos)
Study NCT02652143 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: comparator for embryo culture in vitro
Study NCT02877160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-794 suspension
Study NCT02877160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-794 tablet
Study NCT03484520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: tablet, oral
Study NCT03484520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinaciclib
Description: intravenous
Study NCT00524719 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Reduction and Internal Fixation
Description: Fixation with volar locked plate
Study NCT00524719 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Spanning External Fixation
Description: Radio-radial external fixation
Study NCT00524719 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed Reduction with Percutaneous Fixation
Description: Percutaneous intrafocal pinning (Kapandji technique)
Study NCT01995877 — intervention group
Intervention type: PROCEDURE
Intervention: Subjects scheduled for IVC filter placement
Description: Subjects will have an intra vascular ultrasound (IVUS) performed while lying down on the exam table; this will be performed before and after the IVC (inferior vena cava) filter is placed. During the ultrasound, measurements of the diameter of different areas of the IVC will be taken. The table will then be moved so that you are in a standing position and the measurements will be taken again.~The ultrasound will be done by the physician performing your procedure. When you are lying down, a sheath (small catheter) will be inserted into a vein in your groin. The IVUS (intra vascular ultrasound) catheter will be inserted through the sheath and used to measure the size of the IVC at various places.~The IVUS procedure will add about 30-45 minutes to the filter placement procedure.
Study NCT02685943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Study NCT02685943 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Study NCT04209621 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Duvelisib
Description: twice daily as tolerated until disease progression
Study NCT04209621 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ibrutinib
Description: daily for the first six 28-day cycles
Study NCT04139798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution (0.6% sodium chloride solution)
Study NCT02223403 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nitrate-rich beetroot juice
Description: 3 ounces of nitrate-rich beetroot juice ingested orally once 90 minutes before exercise interventions of steady state treadmill exercise followed 30 minutes later by six minute walk
Study NCT02223403 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nitrate-deplete beetroot juice
Description: 3 ounces of nitrate-deplete beetroot juice ingested orally once 90 minutes before exercise interventions of steady state treadmill exercise followed 30 minutes later by six minute walk
Study NCT05406804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Olfactory stimulation
Description: 1) For the premature infants who use non-invasive ventilation, place a single layer of gauze soaked in breast milk on the air outlet of the non-invasive ventilator. When inhaling oxygen with a high-flow nasal cannula, the same measure is performed, and the breast milk and sterile gauze soaked in breast milk are replaced every 4 hours. 2) For the premature infants who withdrawn from assisted ventilation, place the breast pad near the infants' nose, and replace the breast milk pad every 4 hours. Acquisition of breast milk pads: use the same brand of breast milk pads; put the breast milk pads used between 00:00 and 07:00 every day (use time > 2 hours) into the same brand of milk storage bags, and use two left and right at the same time. 3) If the premature infants don't have any ventilation support, the breast milk stimulation method is the same as 2). This intervention will continue until premature infants discharge from hospital.
Study NCT05406804 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine nursing care
Description: Nursing is performed according to existing nursing practices. Nasal feeding is generally used.
Study NCT02962544 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FS-SMILE
Description: The procedure will be performed using an established technique. the patient's eye will be centered and docked with the curved interface cone before application of suction fixation.The laser will be activated for photo-dissection in the following sequence: first the posterior surface of the refractive lenticule then the lenticule border then The anterior surface of the refractive lenticule which extended beyond the posterior lenticule diameter by 0.5 mm to form the anterior flap and is followed by a rim cut. After the suction is released, a Siebel spatula is inserted under the cap near the hinge before the cap is separated. The edge of the refractive lenticule is separated from the stromal bed with a sinsky hook and the posterior border of the lenticule gently separated with the Siebel spatula. The lenticule is then grasped with forceps through the small incision.
Study NCT02962544 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FS- LASIK
Description: LASIK procedure Each LASIK procedure will be performed using a standard, established technique. Under topical anesthesia and standard draping, a lid speculum is used to retract the eyelids. A superiorly hinged 100 μm thick flap will be created using the WaveLight FS200 (Alcon Laboratories, Inc.) With inverted side cut (115 ̊) .Excimer laser ablation is then performed using WaveLight EX500 excimer laser (Alcon Laboratories, Inc.).After ablation, the flap will be carefully repositioned, and postoperative medications are commenced.
Study NCT02962544 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visumax device
Study NCT02962544 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FS 200 device
Study NCT02147665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hookah smoking
Description: Subjects will smoke waterpipe in a controlled research environment.
Study NCT04395703 — intervention group
Intervention type: OTHER
Intervention: Interviews and focus groups
Description: Unstructured and semi-structured interviews with open ended questions.
Study NCT01543724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: 10mg/kg/day for 12 weeks
Study NCT02271997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous fumarate
Description: treatment with ferrous fumarate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
Study NCT02271997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous gluconate
Description: treatment with ferrous gluconate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
Study NCT02271997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron(III)carboxymaltose
Description: treatment with Iron(III)carboxymaltose and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
Study NCT01067326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: 150 mg Aliskiren once daily for a period of 4 months
Study NCT01067326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill per day by mouth for 4 months
Study NCT01230788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2/dose on days 8, 15, 22, and 29 (diluted in NS to a final concentration of 1 mg/ml for ease of administration). (Premedicate with Acetaminophen 15 mg/kg po (max 650 mg) and Diphenhydramine 1 mg/kg IV/PO (max 50 mg)).
Study NCT01610362 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Rabies Immune Globulin
Description: HRIG 20 IU/kg and 40 IU/kg would be given once to the volunteers on day 0
Study NCT01610362 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Rabies Immune Globulin
Description: HRIG 20 IU/kg and 40 IU/kg would be given once to the volunteers on day 0
Study NCT01740323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily placebo for 6 weeks
Study NCT01740323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: 500 mg BID
Study NCT04743154 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: In-hospital nonculprit-lesions percutaneous coronary intervention (PCI)
Description: To perform percutaneous coronary intervention of non-culprit vessels in a staged procedure during index admission.
Study NCT04743154 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: After-discharge nonculprit-lesions percutaneous coronary intervention (PCI)
Description: To perform percutaneous coronary intervention of non-culprit vessels in a staged procedure after hospital discharge.
Study NCT00751842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhGAD65
Description: Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
Study NCT00751842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhGAD65
Description: Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
Study NCT00751842 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injected subcutaneously at days 1, 30, 90 and 270.
Study NCT02182570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WAL 801 CL dry syrup
Study NCT00969046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO906 (patupilone)
Study NCT02393274 — intervention group
Intervention type: DEVICE
Intervention: Extra-corporeal membrane oxygenation life support
Description: venoarterial extra-corporeal membrane oxygenation life support
Study NCT03047759 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: water flosser
Description: Powered
Study NCT03047759 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: air floss
Description: Powered
Study NCT02626754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib malate
Description: Sunitinib 50mg will be given for 2 consecutive weeks then followed by one week of rest.
Study NCT03181451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Maltol
Description: To assess the pharmacokinetics and iron uptake of Ferric Maltol through measurement of serum iron, transferrin saturation (TSAT) and plasma concentrations of maltol and maltol glucuronide.
Study NCT02141789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outpatient Cognitive Behavioral Psychotherapy
Description: Integrated CBT intervention for alcohol dependence and comorbid psychiatric disorder (we include only patients with comorbid mood or anxiety disorders).
Study NCT02141789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outpatient Cognitive Behavioral Psychotherapy
Description: The intervention is a well established form of psychotherapy that has infrequently been used in the German system with this group of patients in contrast to many other countries where it is the standard approach, e.g. the US.
Study NCT01809184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin 287
Description: Orally administered insulin 287. The subjects will be dosed in the fasting state and receive one single dose followed by a 24-hour euglycaemic glucose clamp.
Study NCT01809184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Insulin glargine administered subcutaneously (s.c., under the skin) at fixed dose levels.
Study NCT01809184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral placebo adminstered corresponding to insulin 287 treatment
Study NCT01937325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivacaftor
Description: active arm
Study NCT01937325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: active arm
Study NCT04030507 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI (which stands for magnetic resonance imaging) provide imaging of the brain which help look for brain metastases (spread of the breast cancer to the brain).
Study NCT01695915 — intervention group
Intervention type: PROCEDURE
Intervention: Transabdominal ultrasound
Description: Transabdominal ultrasound are applied to the subjects every third hour during the study and every hour for three hours after a bowel movement.
Study NCT02042196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUVAN
Description: KUVAN will be given orally at 10mg/kg dose per body weight. KUVAN will be dissolved in 4-8oz water and consumed within 15 minutes.
Study NCT02042196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo pills designed to match the dissolvable KUVAN pills
Study NCT02042196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrotide
Description: Cetrotide (0.25mg/d) will be taken daily for 10 days via abdominal subcutaneous injection.
Study NCT02042196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Climara
Description: 0.075mg/d transdermal patch will be placed on skin.
Study NCT02042196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo transdermal patch
Description: Inactive transdermal patch
Study NCT04384848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMPATHY Pilot
Description: The goal of this pilot is to develop and pilot a tailored monitoring intervention targeting symptomatic, Patient-reported adverse events (AEs) in chronic myeloid leukemia (CML) Patients undergoing first-line tyrosine kinase inhibitor (TKI) therapy. The tailored monitoring intervention will draw primarily from the PRO-CTCAE Item Library, with additional items drawn from the FACIT and EORTC Item libraries as necessary. After identifying the full set of AEs to be monitored, we will load the Patient assessment and report program into tablets for electronic administration in the busy clinic setting. We will then pilot a six-month intervention aimed to monitor and manage emerging AEs, coupled with assessment of intervention feasibility, Patient acceptability and satisfaction, provider acceptability and clinical management utility, adherence to TKI therapy, and HRQoL. We expect that adherence to therapy, clinical response, and HRQoL will be enhanced by such an intervention.
Study NCT02196714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium and Formoterol Fumarate (GFF) Dose 1
Description: Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)
Study NCT02196714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium and Formoterol Fumarate (GFF) Dose 2
Description: Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)
Study NCT02196714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium (GP) Dose 1
Description: Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)
Study NCT02196714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium (GP) Dose 2
Description: Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)
Study NCT04615767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-chiro-inositol
Description: as described previously
Study NCT01185925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil, 50 mg 3 times/day
Study NCT01185925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02453360 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block
Description: Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
Study NCT02453360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block
Description: Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
Study NCT03321734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Infants will be started on oral caffeine base at 5 mg/kg/day. At 36 weeks + 0 days PMA drug dose will be increased to 5 mg/kg BID (total daily dose 10 mg/kg). Dose will be weight-adjusted weekly until NICU (neonatal intensive care unit) discharge. After discharge, all new doses will be calculated from the last weight recorded prior to discharge. The research pharmacy will prepare a bulk oral solution with active drug (caffeine base). While in the hospital, a daily 24-hour supply will be prepared and dispensed. For home administration of study drug, the research pharmacy at each clinical site will prepare and dispense a sufficient quantity of caffeine base solution for outpatient treatment up to 42 weeks + 6 days.
Study NCT03321734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: SyrSpend SF Unflavored will be used as the placebo for the control group infants. The volume of the placebo will match the volume of the study drug.
Study NCT05051137 — intervention group
Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Initiation of infliximab in any dose and frequency of administration. Could be discontinued for safety reasons and replaced by etanercept.
Study NCT05051137 — intervention group
Intervention type: DRUG
Intervention: Sulfasalazine + Hydroxychloroquine
Description: Initiation of sulfasalazine and hydroxychloroquine not more than 180 days apart, in any dose and frequency of administration. Any one of the two drugs could be discontinued. while continuing the other, or both could be replaced by cyclosporine, for safety reasons.
Study NCT04071353 — intervention group
Intervention type: DRUG
Intervention: Interferon
Description: Interferon combined with ribavirin antiviral therapy
Study NCT04071353 — intervention group
Intervention type: DRUG
Intervention: ribavirin
Description: Interferon combined with ribavirin antiviral therapy
Study NCT04071353 — intervention group
Intervention type: DRUG
Intervention: DAAs
Description: DAAs antiviral treatment
Study NCT00261001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transcutaneous mode of administration
Study NCT00261001 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular mode of administration
Study NCT04581616 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrathoracic Intercostal Nerve Block
Description: Injection of local anesthetic into the subcostal groove, to achieve analgesia for chest region.
Study NCT04581616 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: Injection of local anesthetic in the plane deep to the erector spinae muscles and superficial to the transverse processes, to achieve analgesia for chest region.
Study NCT00642551 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: menaquinone-7
Description: 180 µg menaquinone-7 daily for three years
Study NCT00642551 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 placebo capsule daily for three years
Study NCT02600455 — intervention group
Intervention type: DRUG
Intervention: Orencia
Study NCT00629655 — intervention group
Intervention type: OTHER
Intervention: motor task, sensory stimulation
Description: motor task: finger tapping, simple type and complex type~sensory stimulation: electric or tactile stimulation